Biktarvy 必妥维 (Bictegravir/Emtricitabine/Tenofovir Alafenamide) 50mg/200mg/25mg*30's | HIV-1 | GLT

Generic Information: Biktarvy (China-Mainland)

Biktarvy is the Chinese-market version of Gilead's three-drug single-tablet regimen, known in China as Bi Tuo Wei (必妥维) and by its Chinese generic name Bi Ke En Bing Nuo Pian (比克恩丙诺片). Each film-coated tablet contains bictegravir 50 mg, emtricitabine 200 mg, and tenofovir alafenamide 25 mg. It was approved by China's National Medical Products Administration in August 2019 through a priority review pathway and launched in January 2020, roughly a year and a half after its US debut.

What Is Biktarvy Used For?

In China, Biktarvy is used to treat HIV-1 infection in adults who have no current or prior evidence of resistance to integrase inhibitors, emtricitabine, or tenofovir. As a complete once-daily regimen it is prescribed both to people starting antiretroviral therapy for the first time and to those switching from a stable regimen. Its single-pill convenience is regarded by Chinese clinicians as a key driver of long-term treatment adherence.

How Does Biktarvy (BIC/FTC/TAF) Work?

Biktarvy pairs bictegravir, an integrase strand transfer inhibitor that blocks HIV from integrating into host DNA, with two nucleoside reverse transcriptase inhibitors — emtricitabine and tenofovir alafenamide — that halt viral reverse transcription. This two-mechanism, three-drug attack suppresses viral load quickly and durably. The tenofovir alafenamide form was chosen for its improved kidney and bone safety profile compared with the older tenofovir disoproxil fumarate.

Indications

Biktarvy is indicated in China for the treatment of HIV-1 infection in adults. The Chinese label restricts use to patients without current or prior resistance to the integrase inhibitor class, emtricitabine, or tenofovir. It is a complete regimen and must not be combined with other antiretrovirals. It does not cure HIV, so continued specialist monitoring remains essential.

Dosage

The Chinese dose is one tablet once daily, with or without food, and the film-coated tablet should be swallowed whole, not chewed or crushed. If a dose is missed by less than 18 hours it should be taken as soon as possible; if more than 18 hours have passed, that dose is skipped and the normal schedule resumes. If vomiting occurs within one hour of dosing, another tablet is taken. Biktarvy is not recommended when creatinine clearance is below 30 mL per minute or in severe hepatic impairment.

Side Effects

The most common adverse reactions in Chinese and global studies are headache, diarrhea, and nausea, generally mild. Bictegravir can raise serum creatinine by blocking its tubular secretion without changing true kidney filtration, and total bilirubin may rise in some patients. As with all products containing emtricitabine and tenofovir, there is a warning about acute hepatitis B flare on discontinuation, and rare risks of lactic acidosis and immune reconstitution syndrome.

Storage

Store Biktarvy at room temperature in its original packaging, protected from moisture and out of the reach of children. It does not require refrigeration or any special cold-chain handling.

Why Choose China-Sourced Biktarvy?

For buyers sourcing from China, Biktarvy offers genuine Gilead product at the Chinese market price, which — after inclusion in China's national reimbursement system — is substantially lower than the US list price. China's priority-review approval and the medicine's inclusion in national treatment guidelines make it a well-documented, quality-assured option. GLT connects international buyers to this China-Mainland originator supply with clear provenance and export documentation.

How to Order

To source China-Mainland Biktarvy through GLT, contact us on WhatsApp at +86 15234153837 or email [email protected]. Specify the strength, pack size, and your destination, and we will confirm sourcing origin, availability, and the documents required for legal import. We support hospitals, pharmacies, and individual patients.

FAQ

What is Biktarvy called in China? Its Chinese brand name is Bi Tuo Wei (必妥维) and its Chinese generic name is Bi Ke En Bing Nuo Pian (比克恩丙诺片).

When was Biktarvy approved in China? It received NMPA approval in August 2019 through a priority review and was launched in the Chinese market in January 2020.

Is Biktarvy reimbursed in China? Biktarvy has been included in China's national medical insurance drug list, which reduces the out-of-pocket cost for eligible patients.